Titan Net Tangible Assets vs Common Stock Analysis

TTNP Stock

USD 3.96 0.32 8.79%

Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Net Tangible Assets and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Net Tangible Assets vs Common Stock

Net Tangible Assets vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Net Tangible Assets account and Common Stock. At this time, the significance of the direction appears to have weak relationship.

The correlation between Titan Pharmaceuticals' Net Tangible Assets and Common Stock is 0.38. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Common Stock in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Net Tangible Assets and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Titan Pharmaceuticals are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Net Tangible Assets i.e., Titan Pharmaceuticals' Net Tangible Assets and Common Stock go up and down completely randomly.

Correlation Coefficient

0.38

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Common Stock

Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.As of 12/04/2024, Sales General And Administrative To Revenue is likely to grow to 52.45, while Selling General Administrative is likely to drop slightly above 5.4 M.

Titan Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Common Stock Total Equity	Short Term Investments	Property Plant Equipment
Total Assets		0.59	-0.3	0.71	-0.11	0.69	-0.64	-0.02	0.74	0.95	0.08	-0.35	0.97	0.85	-0.47	0.45	-0.56	0.59	0.99	0.32	-0.35	0.09	0.7	0.66	-0.33	0.68
Short Long Term Debt Total	0.59		-0.34	0.68	-0.65	0.43	0.17	0.47	0.73	0.43	0.33	-0.17	0.46	0.66	-0.75	0.79	-0.86	0.82	0.54	0.68	0.15	-0.33	0.73	0.78	0.13	0.12
Other Current Liab	-0.3	-0.34		-0.18	0.2	0.1	0.12	0.11	-0.42	-0.35	0.28	0.11	-0.32	-0.47	-0.16	-0.35	0.32	-0.32	-0.34	-0.22	0.3	0.09	-0.47	-0.44	0.27	-0.14
Total Current Liabilities	0.71	0.68	-0.18		-0.62	0.65	-0.11	0.3	0.54	0.62	0.42	-0.21	0.64	0.58	-0.49	0.66	-0.58	0.85	0.65	0.44	0.1	0.16	0.48	0.52	0.09	0.55
Total Stockholder Equity	-0.11	-0.65	0.2	-0.62		-0.03	-0.61	-0.28	-0.25	-0.01	-0.17	0.31	-0.03	-0.18	0.3	-0.9	0.32	-0.87	-0.09	-0.22	-0.23	0.16	-0.15	-0.19	-0.19	0.15
Property Plant And Equipment Net	0.69	0.43	0.1	0.65	-0.03		-0.4	0.23	0.59	0.52	0.53	-0.1	0.57	0.54	-0.7	0.15	-0.49	0.36	0.61	0.34	0.01	0.36	0.45	0.46	0.0	0.8
Net Debt	-0.64	0.17	0.12	-0.11	-0.61	-0.4		0.39	-0.32	-0.73	0.2	0.16	-0.72	-0.48	-0.11	0.31	0.06	0.17	-0.67	0.05	0.55	-0.35	-0.36	-0.28	0.49	-0.66
Retained Earnings	-0.02	0.47	0.11	0.3	-0.28	0.23	0.39		0.12	-0.19	0.9	0.67	-0.17	0.02	-0.53	0.11	-0.58	0.2	-0.15	0.81	0.91	-0.24	0.1	0.27	0.92	-0.11
Accounts Payable	0.74	0.73	-0.42	0.54	-0.25	0.59	-0.32	0.12		0.58	0.11	-0.38	0.61	0.93	-0.58	0.52	-0.73	0.57	0.73	0.47	-0.26	-0.02	0.8	0.79	-0.24	0.44
Cash	0.95	0.43	-0.35	0.62	-0.01	0.52	-0.73	-0.19	0.58		-0.1	-0.36	0.99	0.75	-0.24	0.36	-0.42	0.49	0.97	0.2	-0.47	0.1	0.64	0.58	-0.44	0.64
Non Current Assets Total	0.08	0.33	0.28	0.42	-0.17	0.53	0.2	0.9	0.11	-0.1		0.6	-0.07	0.02	-0.57	-0.01	-0.46	0.16	-0.06	0.66	0.85	0.08	0.01	0.17	0.85	0.21
Non Currrent Assets Other	-0.35	-0.17	0.11	-0.21	0.31	-0.1	0.16	0.67	-0.38	-0.36	0.6		-0.36	-0.41	0.02	-0.51	-0.11	-0.44	-0.43	0.45	0.75	-0.04	-0.24	-0.1	0.77	-0.24
Cash And Short Term Investments	0.97	0.46	-0.32	0.64	-0.03	0.57	-0.72	-0.17	0.61	0.99	-0.07	-0.36		0.75	-0.29	0.37	-0.45	0.51	0.98	0.22	-0.45	0.11	0.66	0.6	-0.43	0.64
Net Receivables	0.85	0.66	-0.47	0.58	-0.18	0.54	-0.48	0.02	0.93	0.75	0.02	-0.41	0.75		-0.43	0.49	-0.63	0.57	0.85	0.4	-0.34	-0.05	0.76	0.72	-0.31	0.55
Common Stock Shares Outstanding	-0.47	-0.75	-0.16	-0.49	0.3	-0.7	-0.11	-0.53	-0.58	-0.24	-0.57	0.02	-0.29	-0.43		-0.39	0.73	-0.47	-0.38	-0.59	-0.27	0.26	-0.53	-0.6	-0.24	-0.22
Non Current Liabilities Total	0.45	0.79	-0.35	0.66	-0.9	0.15	0.31	0.11	0.52	0.36	-0.01	-0.51	0.37	0.49	-0.39		-0.44	0.95	0.45	0.21	-0.07	-0.21	0.41	0.4	-0.1	0.0
Other Stockholder Equity	-0.56	-0.86	0.32	-0.58	0.32	-0.49	0.06	-0.58	-0.73	-0.42	-0.46	-0.11	-0.45	-0.63	0.73	-0.44		-0.53	-0.49	-0.9	-0.22	0.23	-0.86	-0.94	-0.24	-0.18
Total Liab	0.59	0.82	-0.32	0.85	-0.87	0.36	0.17	0.2	0.57	0.49	0.16	-0.44	0.51	0.57	-0.47	0.95	-0.53		0.57	0.32	-0.01	-0.08	0.48	0.48	-0.03	0.22
Total Current Assets	0.99	0.54	-0.34	0.65	-0.09	0.61	-0.67	-0.15	0.73	0.97	-0.06	-0.43	0.98	0.85	-0.38	0.45	-0.49	0.57		0.23	-0.47	0.07	0.7	0.64	-0.45	0.65
Short Term Debt	0.32	0.68	-0.22	0.44	-0.22	0.34	0.05	0.81	0.47	0.2	0.66	0.45	0.22	0.4	-0.59	0.21	-0.9	0.32	0.23		0.54	-0.29	0.62	0.75	0.58	0.07
Other Current Assets	-0.35	0.15	0.3	0.1	-0.23	0.01	0.55	0.91	-0.26	-0.47	0.85	0.75	-0.45	-0.34	-0.27	-0.07	-0.22	-0.01	-0.47	0.54		-0.15	-0.29	-0.11	1.0	-0.27
Property Plant And Equipment Gross	0.09	-0.33	0.09	0.16	0.16	0.36	-0.35	-0.24	-0.02	0.1	0.08	-0.04	0.11	-0.05	0.26	-0.21	0.23	-0.08	0.07	-0.29	-0.15		-0.14	-0.17	-0.15	0.46
Common Stock	0.7	0.73	-0.47	0.48	-0.15	0.45	-0.36	0.1	0.8	0.64	0.01	-0.24	0.66	0.76	-0.53	0.41	-0.86	0.48	0.7	0.62	-0.29	-0.14		0.98	-0.26	0.3
Common Stock Total Equity	0.66	0.78	-0.44	0.52	-0.19	0.46	-0.28	0.27	0.79	0.58	0.17	-0.1	0.6	0.72	-0.6	0.4	-0.94	0.48	0.64	0.75	-0.11	-0.17	0.98		-0.08	0.26
Short Term Investments	-0.33	0.13	0.27	0.09	-0.19	0.0	0.49	0.92	-0.24	-0.44	0.85	0.77	-0.43	-0.31	-0.24	-0.1	-0.24	-0.03	-0.45	0.58	1.0	-0.15	-0.26	-0.08		-0.24
Property Plant Equipment	0.68	0.12	-0.14	0.55	0.15	0.8	-0.66	-0.11	0.44	0.64	0.21	-0.24	0.64	0.55	-0.22	0.0	-0.18	0.22	0.65	0.07	-0.27	0.46	0.3	0.26	-0.24

Click cells to compare fundamentals

Titan Pharmaceuticals Account Relationship Matchups

Titan Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Short Long Term Debt Total	4.4M	809K	299K	187K	565K	536.8K
Other Current Liab	1.9M	2.3M	1.4M	1.5M	519K	493.1K
Total Current Liabilities	3.6M	4.2M	2.7M	2.6M	1.4M	1.4M
Total Stockholder Equity	1.4M	3.5M	5.1M	1.4M	6.6M	6.3M
Property Plant And Equipment Net	1.2M	759K	717K	407K	68K	64.6K
Net Debt	(782K)	(4.6M)	(5.7M)	(2.8M)	(6.2M)	(6.5M)
Retained Earnings	(349.0M)	(367.3M)	(376.1M)	(386.3M)	(391.8M)	(372.2M)
Accounts Payable	1.4M	1.3M	795K	695K	348K	330.6K
Cash	5.2M	5.4M	6.0M	2.9M	6.8M	8.3M
Non Current Assets Total	1.2M	759K	765K	455K	68K	64.6K
Non Currrent Assets Other	794K	(1.2M)	(759K)	48K	(1.0)	(0.95)
Cash And Short Term Investments	5.2M	5.4M	6.0M	2.9M	6.8M	6.4M
Net Receivables	993K	884K	112K	36K	1.0M	1.6M
Common Stock Shares Outstanding	1.3K	188.7K	486.5K	671.7K	752K	789.6K
Liabilities And Stockholders Equity	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Non Current Liabilities Total	3.8M	4.5M	332K	187K	65K	0.0
Other Stockholder Equity	350.4M	370.8M	381.2M	387.6M	398.5M	418.4M
Total Liab	8.1M	4.6M	2.9M	2.7M	1.4M	1.4M
Total Current Assets	8.3M	7.3M	7.2M	3.6M	8.0M	7.6M
Short Term Debt	272K	627K	224K	244K	565K	1.1M
Other Current Assets	1.1M	703K	787K	524K	199K	189.1K
Property Plant And Equipment Gross	1.2M	618K	2.1M	2M	774K	883.3K
Common Stock	57K	7K	10K	15K	1K	950.0
Property Plant Equipment	794K	1.2M	759K	717K	824.6K	826.4K
Long Term Debt	3.6M	3.8M	4.0M	332K	298.8K	283.9K
Retained Earnings Total Equity	(323.3M)	(332.6M)	(349.0M)	(367.3M)	(330.6M)	(347.1M)
Net Tangible Assets	6.8M	1.4M	3.5M	5.1M	4.6M	4.7M
Capital Surpluse	26.3M	339.4M	350.4M	370.8M	426.4M	447.7M
Net Invested Capital	5.5M	4.2M	5.1M	1.4M	7.1M	4.8M

Pair Trading with Titan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Titan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Titan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Titan Stock

0.89	ETON	Eton Pharmaceuticals Downward Rally	Pair Corr
0.88	VRNA	Verona Pharma PLC	Pair Corr
0.82	EWTX	Edgewise Therapeutics	Pair Corr
0.81	ELDN	Eledon Pharmaceuticals	Pair Corr
0.46	DSGN	Design Therapeutics	Pair Corr

The ability to find closely correlated positions to Titan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Titan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Titan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Titan Pharmaceuticals to buy it.

The correlation of Titan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Titan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Titan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Titan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC